Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis-Reference-Cited by-同舟云学术

Lesion Penetration and Activity Limit the Utility of Second-Line Injectable Agents in Pulmonary Tuberculosis

Published:2021-09-17 Issue:10 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ernest Jacqueline P.¹,Sarathy Jansy²,Wang Ning²,Kaya Firat²,Zimmerman Matthew D.²,Strydom Natasha¹,Wang Han²,Xie Min²,Gengenbacher Martin²³^ORCID,Via Laura E.⁴⁵,Barry Clifton E.⁴⁵,Carter Claire L.²,Savic Radojka M.¹^ORCID,Dartois Véronique²³^ORCID

Affiliation:

1. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA

2. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA

3. Hackensack School of Medicine, Hackensack Meridian Health, Nutley, New Jersey, USA

4. Tuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, Maryland, USA

5. Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, South Africa

Abstract

Amikacin and kanamycin are second-line injectables used in the treatment of multidrug-resistant tuberculosis (MDR-TB) based on the clinical utility of streptomycin, another aminoglycoside and first-line anti-TB drug. While streptomycin was tested as a single agent in the first controlled TB clinical trial, introduction of amikacin and kanamycin into MDR-TB regimens was not preceded by randomized controlled trials.

Funder

Bill and Melinda Gates Foundation

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00506-21

Reference77 articles.

1. Aminoglycosides: An Overview

2. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis